Celsus Laboratories

HEPARIN SALTS

Elemental analysis of typical batches of heparin results in 24.0 - 25% carbon, 3.4 - 3.6% hydrogen, 1.9 - 2.3% nitrogen, and 9.5 - 11.0% sulfur. Heparin salts are strongly anionic polyelectrolytes that effectively bind and release of micro-ions. Activity measurements made with an ion-specific electrode show that only 66 percent of the sodium ions in sodium heparin are bound. Heparin sodium may be converted into different salt forms by passage through appropriately charged cation-exchange resins. Mass spectrometry show a greater than 99% efficiency of the cation exchange process. Of all cations, lithium is most similar to hydrogen and binds to heparin particularly strongly. The rate of heparin-catalyzed thrombin-antithrombin (TAT) interaction, however, is apparently less in the presence of lithium than in the presence of sodium or potassium ions in solutions of similar ionic strength. Of all the cations, lithium binds to heparin with particularly high affinity. Heparin sodium also appears somewhat more resistant to dehydration than heparin lithium. It has been suggested that lyophilized or crystallized lithium heparin is the best anticoagulant for use in blood because it avoids interference with sodium determinations of heparin sodium. Replacement of lithium ions by equivalents of calcium in aqueous solution at pH 7.0 results in a decrease in pH, suggesting a direct involvement of the carboxy groups of heparin in cation interactions. The pH, therefore, may change slightly during blood gas analysis due to the effect of calcium or calcium. Divalent cations such as calcium and zinc bind more strongly to heparin than monovalent counterions. NMR data conclude that calcium ions also are located at specific chelated sites within the heparin molecule. Also, zinc ions bind preferentially to heparin rather than other glycosaminoglycans.

Much of its polysaccharide structure can be represented as a repeating, trisulfated disaccharide and regions containing disulfated disaccharides and disaccharides lacking a sulfate on C-6 of the glucosamine residue are typically present. Activity measurements made with an ion-specific electrode showed that only 66 percent of the sodium ions in heparin are bound. A pentasaccharide containing the unique trisulfated glucosamine residue has high affinity for antithrombin (AT). The binding of heparin to AT accelerates the rate of thrombin inhibition by AT which accounts for the anticoagulant action of heparin. Approximately 30% of the heparin chain contains the pentasaccharide sequence required for binding to AT. The remaining 70% has no AT-dependent anticoagulant activity but catalyzes the inhibition of thrombin by heparin cofactor II. During the clotting process, heparin also will catalyze the inhibition of factor Xa by AT.

BENZALKONIUM HEPARIN [HB-0318] is a water-insoluble salt of heparin sodium USP of porcine intestinal mucosa and benzalkonium chloride NF. Positive amine radicals of primary, secondary and tertiary amines and quaternary ammonium compounds electrostatically bind to negative sulfate radicals of heparin. Quaternary ammonium salts physically bind to adsorptive surfaces because of potent surface-active properties. Benzalkonium Heparin coatings may be further stabilized by exposure to gamma radiation, gas plasma or an electron beam energy source.

References

Amplatz K. A simple non-thrombogenic coating. Invest Radiol 1971; 6: 280-8.
Grode GA, Anderson SJ, Grotta HM, Falb RD. Nonthrombogenic material via a simple coating process. Trans Amer Soc Artif Intl Organs 1969; XV:1- 6.
Helmus M, Scott MJ. Enhanced biocompatibility coatings for medical implants. PCT Int Appl WO 99/38547 (1999).
Ding Ni, Raeder-Devens JE, Trinh TT. Drug-release coatings from medical devices. US Patent 5879697 (1999).
Roorda WE. Medical device and drug for inhibiting formation of thrombus-inflammatory cellmatrix. PCT Int. Appl. WO 01 47,572 (2001).

HEPARIN AMMONIUM [HA-0306] is produced from heparin sodium by cation exchange chromatography pursuant to FDA Drug Master File 8003.

References

Gerstner JA, Cramer SM. Heparin as a nontoxic displacer for anion-xxchange protein displacement systems. BioPharm 1992; 5: 42-5.

HEPARIN CALCIUM [HC-0304] is manufactured pursuant to FDA Drug Master File 7951 from heparin sodium USP of porcine intestinal mucosa. Its quality is guaranteed to meet or exceed the compendial standards of the European, Japanese and U.S. Pharmacopeia.

References

Cade JF, Andrews JT, Stubbs AE. Comparison of Sodium and Calcium Heparin in Prevention of Venous Thromboembolism. Aust NZ J Med 1982; 12: 501-4.
Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP. Heparin and Modified Heparin Inhibit Complement Activation In Vivo. J Immunol 1992; 148: 3210-15.

HEPARIN LITHIUM [HL-0307] is prepared from heparin sodium of porcine intestinal mucosa by cation exchange chromatography. It is the anticoagulant of choice when determining specific analytes in whole blood, and is guaranteed to meet the standards of quality for additives to blood collection devices recommended by the National Committee for Clinical Laboratory Standards. Lithium binds to heparin with particularly high affinity. The rate of heparin-catalyzed thrombin-antithrombin interaction, however, is apparently less in the presence of lithium than in the presence of sodium or potassium ions in solutions of similar ionic strength. Heparin Lithium is the least likely to interfere with other ions, especially when balanced with calcium or zinc chloride.

References

Pedersen LC, Jorgensen M. Biochem J 1983; 211: 91-97.
Grant D, Long WF, Williamson FB. Infrared spectroscopy of heparin-cation complexes. Biochem J 1987; 244: 143-149.
National Committee for Clinical Laboratory Standards. Additives to blood collection devices: heparin. NCCLS Document 1989; 8: 33-53.
Eisenhardt AR, Hansen M. Composition and sampling receptacle method for treating blood with anticoagulant. U.S. Patent 4,687,000 (1987).
Landt M, Hortin GL, Smith CH, McClellan A, Scott MG. Interference in ionized calcium measurements by heparin salts. Clin Chem 1994; 40/4: 565-70.
Toffaletti J. et al. Effects of blended lithium-zinc heparin on ionized calcium and general clinical chemistry tests. Clin Chem 1995; 41: 328-9.

HEPARIN SODIUM [PH-0300] of porcine intestinal mucosa is a bulk drug substance having a molecular weight ranging from 3,000 to 30,000 Daltons with an average of about 12,500. Its strength, quality and purity meet the specifications of the United States Pharmacopeia. In addition, its porcine raw material tests negative for prion antigens and is purified using a process validated for the removal of TSE infectious agents and viral infectivity due to retroviruses, enterohepatic viruses and porcine parvovirus.

Heparin Sodium USP defines chemical specifications and not necessarily the intended use of the product which may be as a bulk drug substance for further manufacture, as an ingredient for the collection and analysis of blood, as a component of nonthrombogenic coatings for blood-interacting medical devices, as an affinity ligand in the purification of heparin-binding proteins, or as a starting material for low molecular weight heparins and heparin lyases.

References

Dunstone JR. Ion-Exchange Reactions between Acid Mucopolysaccharides and Various Cations. Biochem J 1962; 85: 336-51.
Kotoku T, Yosizawa Z, Yamauchi F. Comparison of heparin specimens isolated from bovine, porcine and whale organs. Arch Biochem Biophys 1967; 120: 553-62.
Sullivan JD, Watson SW. Inhibitory effect of heparin on the Limulus test for endotoxin. J Clin Microbiol 1975; 2:155.
Casu B. Structure and biological activity of heparin. Adv Carbohydr Chem Biochem 1985;43:51-134.

HEPARIN ZINC LITHIUM [LZ-0308] is produced from Heparin Sodium of porcine intestinal mucosa by cation exchange chromatography. It is an anticoagulant specifically designed for the potentiometric determination of electrolytes in blood. Of all cations, lithium is most similar to hydrogen and binds to heparin particularly strongly. Divalent cations such as calcium and zinc bind more strongly to heparin than monovalent counterions. Also, zinc ions bind preferentially to heparin rather than other glycosaminoglycans.

References

Parrish RF, Fair WR. Selective Binding of zinc ions to heparin rather than to other glycosaminoglycans. Biochem J 1981; 193: 407-10.
Woodhead NE, Long WF, Williamson FB. Binding of zinc ions to heparin. Biochem J 1986; 237: 281-281.
Mattai J, Kwak JCT. Quantitative similarity of zinc and calcium binding to heparin in excess salt solution. Biophys Chem 1988; 31: 295-9.

STEARALKONIUM HEPARIN [SK-0317] is a water-insoluble salt of heparin sodium of porcine intestinal mucosa and stearyldimethylbenzylammonium chloride.

References

Gott VL, Whiffin JD, Dutton RC. Heparin bonding on colloidal graphite surfaces. Science 1963; 142: 1297-8.
Eriksson JC. Method for making nonthrombogenic surfaces. US Patent 3,634,123 (1972).

Back to top inquiries@heparin.com
© 2001